 Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: New progress in immunotherapy!

ASCO 2021: New progress in immunotherapy!

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

global scent company

supragastric belching treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 4, 2021, the annual event of the global oncology community-the American Society of Clinical Oncology ( ASCO ) annual meeting officially kicked off.

ASCO clinical trial digestion

RATIONALE 302 study is the digestive tract tumor areas first global Phase 3 study as a Leading PI by Chinese researchers, is the first global phase 3 study esophageal squamous cell carcinoma, the data brisk performance, this year's ASCO concern of the research project One.

The tumor

Reference
1, International Agengy for Research on Cancer in 2018, WHO data cancer today.
https://gco.
iarc.
fr/today/explore
2, People’s Republic of China Health Commission.
Esophageal Cancer Diagnosis and Treatment Specifications (2018 Edition) Diagnosis and Treatment
3 , Zhang T, et al.
Cancer Immunol Immunother.
2018;67(7):1079-1090
4, Yingcai Feng, et al.
AACR.
2019; Volume 79, Issue 13 Supplement, pp.
2383
5, Abstract #4048 American Association for Cancer Research March 29-April 3,2019, Atlanta, GA.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

ASCO 2021: New progress in skin cancer immunotherapy (continuous update)

06-10

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

ASCO 2021: New progress in immunotherapy!

Related Articles

ASCO 2021: New progress in skin cancer immunotherapy (continuous update)